Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer

Jung, Young Ju; Oh, In Jae; Kim, Youndong; Jung, Jong Ha; Seok, Minkyoung; Lee, Woochang; Park, Cheol‐Kyu; Lim, Jung Hwan; Kim, Young‐Chul; Kim, Woo-Sung; Choi, Chang‐Min

doi:10.3346/jkms.2018.33.e342

Cited by 7 publications

(4 citation statements)

References 19 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, the SOMAscan technology has been linked to the biomarker discovery of various chronic and acute diseases [ 22 , 24 , 25 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ]. For cancer, the assay is prescribed feasible for hepatocellular carcinoma [ 22 ], ovarian cancer [ 41 , 42 ], non-small lung cancer [ 43 ] and malignant glioma [ 44 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma

Blatt

Kämmerer

Krüger

et al. 2023

Cancers

View full text Add to dashboard Cite

Improved serological biomarkers are needed for the early detection, risk stratification and treatment surveillance of patients with oral squamous cell carcinoma (OSCC). We performed an exploratory study using advanced, highly specific, DNA-aptamer-based serum proteomics (SOMAscan, 1305-plex) to identify distinct proteomic changes in patients with OSCC pre- vs. post-resection and compared to healthy controls. A total of 63 significantly differentially expressed serum proteins (each p < 0.05) were found that could discriminate between OSCC and healthy controls with 100% accuracy. Furthermore, 121 proteins were detected that were significantly altered between pre- and post-resection sera, and 12 OSCC-associated proteins reversed to levels equivalent to healthy controls after resection. Of these, 6 were increased and 6 were decreased relative to healthy controls, highlighting the potential relevance of these proteins as OSCC tumor markers. Pathway analyses revealed potential pathophysiological mechanisms associated with OSCC. Hence, quantitative proteome analysis using SOMAscan technology is promising and may aid in the development of defined serum marker assays to predict tumor occurrence, progression and recurrence in OSCC, and to guide personalized therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma

Blatt

Kämmerer

Krüger

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Alpha-1-antichymotrypsin (SERPINA3) belongs to a superfamily of serine proteinase inhibitors. Although its exact biological function is not known, it has been described in association with diverse pathologies, such as acute kidney injury, cardiovascular disease, and (lung) cancer [ 37 , 38 , 39 , 40 ]. It was described to promote metastasis and the epithelial–mesenchymal transition in breast cancer [ 41 ] and was found to be upregulated in lung cancer in comparison to control patients [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Plasma Proteomics Enable Differentiation of Lung Adenocarcinoma from Chronic Obstructive Pulmonary Disease (COPD)

Bracht

Kleefisch

Schork

et al. 2022

IJMS

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a major risk factor for the development of lung adenocarcinoma (AC). AC often develops on underlying COPD; thus, the differentiation of both entities by biomarker is challenging. Although survival of AC patients strongly depends on early diagnosis, a biomarker panel for AC detection and differentiation from COPD is still missing. Plasma samples from 176 patients with AC with or without underlying COPD, COPD patients, and hospital controls were analyzed using mass-spectrometry-based proteomics. We performed univariate statistics and additionally evaluated machine learning algorithms regarding the differentiation of AC vs. COPD and AC with COPD vs. COPD. Univariate statistics revealed significantly regulated proteins that were significantly regulated between the patient groups. Furthermore, random forest classification yielded the best performance for differentiation of AC vs. COPD (area under the curve (AUC) 0.935) and AC with COPD vs. COPD (AUC 0.916). The most influential proteins were identified by permutation feature importance and compared to those identified by univariate testing. We demonstrate the great potential of machine learning for differentiation of highly similar disease entities and present a panel of biomarker candidates that should be considered for the development of a future biomarker panel.

show abstract

“…Such strategy has been for instance applied to NSCLC serum biomarker studies (Ostroff et al 2010a; Mahan 2014), identifying 44 candidate biomarkers and developing a 12-protein panel able to identify NSCLC from controls with high sensitivity and specificity. Further, a 7-protein biomarker (EGFR1, MMP7, CA6, KIT, CRP, C9 and SERPINA3) panel (AptoDetect™-Lung, Aptamer Sciences, Inc., Pohang, Korea) was developed as aptamer-based proteomic technology to distinguish lung cancers from benign nodule controls [ 39 , 40 ].…”

Section: Nucleic Acid Aptamers For Nsclc Detectionmentioning

confidence: 99%

Advances in Oligonucleotide Aptamers for NSCLC Targeting

Rotoli

Santana-Viera

Ibba

et al. 2020

IJMS

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer worldwide, with the highest incidence in developed countries. NSCLC patients often face resistance to currently available therapies, accounting for frequent relapses and poor prognosis. Indeed, despite great recent advancements in the field of NSCLC diagnosis and multimodal therapy, most patients are diagnosed at advanced metastatic stage, with a very low overall survival. Thus, the identification of new effective diagnostic and therapeutic options for NSCLC patients is a crucial challenge in oncology. A promising class of targeting molecules is represented by nucleic-acid aptamers, short single-stranded oligonucleotides that upon folding in particular three dimensional (3D) structures, serve as high affinity ligands towards disease-associated proteins. They are produced in vitro by SELEX (systematic evolution of ligands by exponential enrichment), a combinatorial chemistry procedure, representing an important tool for novel targetable biomarker discovery of both diagnostic and therapeutic interest. Aptamer-based approaches are promising options for NSCLC early diagnosis and targeted therapy and may overcome the key obstacles of currently used therapeutic modalities, such as the high toxicity and patients’ resistance. In this review, we highlight the most important applications of SELEX technology and aptamers for NSCLC handling.

show abstract

Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer

Cited by 7 publications

References 19 publications

High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma

High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma

Plasma Proteomics Enable Differentiation of Lung Adenocarcinoma from Chronic Obstructive Pulmonary Disease (COPD)

Advances in Oligonucleotide Aptamers for NSCLC Targeting

Contact Info

Product

Resources

About